Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 3,300,000 shares, a decline of 6.8% from the December 15th total of 3,540,000 shares. Approximately 2.6% of the shares of the stock are short sold. Based on an average trading volume of 1,050,000 shares, the short-interest ratio is presently 3.1 days.

Amneal Pharmaceuticals Stock Down 0.6 %

AMRX stock opened at $8.26 on Friday. Amneal Pharmaceuticals has a twelve month low of $5.01 and a twelve month high of $9.48. The firm has a market cap of $2.56 billion, a PE ratio of -12.15 and a beta of 1.10. The business has a 50 day moving average of $8.18 and a 200 day moving average of $8.10.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AMRX. Piper Sandler boosted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Truist Financial upped their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Finally, StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 62,590 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total value of $501,345.90. Following the transaction, the director now owns 1,968,886 shares in the company, valued at $15,770,776.86. This trade represents a 3.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jason B. Daly sold 43,657 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 123,657 shares of company stock worth $1,016,687. 17.46% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in AMRX. Gladius Capital Management LP purchased a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at $37,000. DekaBank Deutsche Girozentrale bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at about $42,000. Xponance Inc. purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at about $65,000. Quest Partners LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $84,000. Finally, Janney Montgomery Scott LLC bought a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $121,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.